Global Med Form 12b-25--Form 10-Q
| |
|
|
Potential persons who are to
respond to the collection of
information contained in this
form are not required to
respond unless the form
displays a currently valid
OMB control number. |
-----------------------------
UNITED STATES OMB APPROVAL
SECURITIES AND EXCHANGE COMMISSION -----------------------------
Washington, D.C. 20549 OMB Number: 3235-0058
Expires: January 31, 2005
Estimated average burden
FORM 12b-25 hours per response ..... 2.50
-----------------------------
-----------------------------
NOTIFICATION OF LATE FILING SEC FILE NUMBER
0-22083
(Check One): -----------------------------
-----------------------------
[ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR CUSIP NUMBER
37935e-10-1
For Period Ended: September 30, 2003 -----------------------------
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: __________________________________________
Read attached instruction sheet before preparing form. Please print or type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates: ________________________
PART I -- REGISTRANT INFORMATION
GLOBAL MED TECHNOLOGIES, INC.
________________________________________________________________________________
Full Name of Registrant
N/A
________________________________________________________________________________
Former Name if Applicable
12600 West Colfax, Suite C-420
________________________________________________________________________________
Address of Principal Executive Office (Street and Number)
Lakewood, Colorado 80215
________________________________________________________________________________
City, State and Zip Code
PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate.)
| (a) The reasons described in reasonable detail in Part III of this
| form could not be eliminated without unreasonable effort or
| expense;
|
[X] | (b) The subject annual report, semi-annual report, transition report
| on Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will
| be filed on or before the 15th calendar day following the
| prescribed due date; or the subject quarterly report or
| transition report on Form 10-Q, or portion thereof will be filed
| on or before the fifth calendar day following the prescribed due
| date; and
|
| (c) The accountant's statement or other exhibit required by Rule
| 12b-25(c) has been attached if applicable.
PART III -- NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
N-SAR, or the transition report or portion thereof, could not be filed within
the prescribed time period.
Registrant has encountered delays in completing its Quarterly Report
on Form 10-Q for the quarter ended September 30, 2003, because the Company
is in the process of obtaining all of the necessary signatures for the
document.
PART IV--OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification
Michael I. Ruxin, M.D (303) 238-2000
________________________________________________________________________________
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is
no, identify report(s).
[X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof?
[X] Yes [ ] No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
For the three months ended September 30, 2003, Registrant
incurred a net loss of approximately $468 thousand on revenues of
approximately $1.279 million. For the three months ended September
30, 2002, registrant incurred a net loss of $410 thousand on
revenues of $1.425 million. The primary reason for the decrease
in revenues was decreased PeopleMed.com revenues and decreased
implementation fees that were partially offset by an increase in
maintenance revenues. The net loss increased primarily because of
the decrease in revenues of $146 thousand partially offset by a
decrease in financing costs of $63 thousand from the comparable
period in 2002.
For the nine months ended September 30, 2003, Registrant
incurred a net loss of approximately $401 thousand compared to a
net loss of $537 thousand for the nine months ended September 30,
2002. For the nine months ended September 30, 2003 and 2002,
Registrant recognized revenues of $5.097 million and $4.838
million, respectively. The primary reason for the decrease in
the net loss is the increase in revenues of $259 and a decrease
in financing costs of $64 thousand, which were partially offset
by an increase in operating expenses of $155 thousand for the
nine months ended September 30, 2003 compared to the similar
period in 2002.
================================================================================
GLOBAL MED TECHNOLOGIES, INC.
------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: November 17, 2003 By /s/ Michael I. Ruxin
-----------------------------------
Michael I. Ruxin, M.D.
Chairman of the Board and
Chief Executive Office
INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (see 18 U.S.C. 1001).